The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Recludix Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $123.5MM | Series B | 1/12/2026 | $21.5MM | $327.7MM | $2.31 | Access Biotechnology, Alexandria Venture Investments, NEA, Westlake Village BioPartners, Eli Lilly | |||||
| Theracos | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $135.86MM | Series C | 9/20/2013 | $93.09MM | $327.39MM | $18.62 | Undisclosed Investors | |||||
| Centrexion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $569.49MM | Series D | 9/30/2019 | $90.34MM | $327.06MM | $1.80 | New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital | |||||
| Baylor Genetics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $102MM | Series A | 3/31/2025 | $102MM | $326MM | $17.88 | Decheng Capital | |||||
| MORE Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $65.85MM | Series D | 11/5/2020 | $21.86MM | $324.48MM | $0.78 | Undisclosed Investors | |||||
| Casana | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $139.73MM | Series B | 1/21/2022 | $30MM | $323.86MM | $12.77 | Morningside, Matrix Partners, General Catalyst, Outsiders Fund | |||||
| ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $199MM | Series B | 9/24/2021 | $149MM | $321.94MM | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | |||||
| Route 92 | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $217.29MM | Series F-2 | 4/7/2026 | $50MM | $321.15MM | $7.13 | Sectoral Asset Management, Novo Holdings, U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, The Vertical Group | |||||
| Phil | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $119.43MM | Series D | 7/3/2021 | $61.34MM | $321.12MM | $4.06 | Warburg Pincus | |||||
| Crystalys Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $205MM | Series A | 9/30/2025 | $205MM | $318.59MM | $1.00 | Novo Holdings, SR One, Catalys Pacific, Perceptive Advisors, Lightstone Ventures, AN Venture Partners, Abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, Prebys Ventures | |||||
| LocanaBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $318MM | Series B | 12/14/2020 | $100MM | $317.84MM | $4.42 | Vida Ventures, RA Capital Management, Invus, Acuta Capital Partners, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures, GV | |||||
| Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $90.87MM | Series C-1 | 8/11/2020 | $13.31MM | $317.71MM | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | |||||
| AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $25.63MM | Series C | 1/14/2025 | $10MM | $317.19MM | $5.05 | Undisclosed Investors | |||||
| MBX Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $216.64MM | Series C | 8/5/2024 | $63.5MM | $316.71MM | $1.03 | Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management | |||||
| Elucid Bioimaging | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $156.63MM | Series D | 10/10/2025 | $36.5MM | $316.49MM | $2.13 | Undisclosed Investors | |||||
| OrsoBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $166.63MM | Series B | 9/6/2024 | $67MM | $316.32MM | $0.71 | Ascenta Capital, Woodline Partners, Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, Eli Lilly and Company | |||||
| EndoQuest Robotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $207.22MM | Series D-2 | 7/14/2025 | $30.74MM | $316.22MM | $0.80 | Crescent Enterprises, Dr. Fred Moll, Puma Venture Capital, UTHealth Houston | |||||
| Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $150.75MM | Series B | 10/15/2025 | $120MM | $314.7MM | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | |||||
| Turquoise Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $96.49MM | Series C | 3/17/2026 | $36.46MM | $314.03MM | $11.72 | Oak HC/FT, Andreessen Horowitz, Adams Street Partners, Yosemite | |||||
| Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $406.62MM | Series C | 5/13/2024 | $106.6MM | $313.67MM | $2.04 | Venrock Healthcare Capital Partners, Janus Henderson Investors, Marshall Wace, Franklin Templeton, Redmile Group, RTW Investments, Blue Owl Healthcare Opportunities, Invus, Eli Lilly and Company, Alexandria Venture Investments | |||||
| Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $225MM | Series B | 7/11/2023 | $150MM | $313.42MM | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | |||||
| Levels | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $365.48MM | Series A-1 | 4/20/2022 | $46.01MM | $311.7MM | $10.44 | Andrea Funsten, Ben Gilbert, David Rosenthal, Lenny Rachitsky, Mario Gabriele, Mat Fraser, Moshe Lifschitz, Niv Dror, Andreessen Horowitz, Trust Ventures, Shrug Capital, TriplePoint Capital, Long Journey Ventures | |||||
| Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $250MM | Series B | 9/7/2023 | $175MM | $311.65MM | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | |||||
| Proclara Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $112.79MM | Series F | 11/7/2018 | $6.92MM | $310.98MM | $0.90 | Undisclosed Investors | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.